Safinamide Mesylate

CAS 202825-46-5 9 API suppliersSmall Molecule

Overview

Safinamide Mesylate is a selective monoamine oxidase B (MAO-B) inhibitor with both dopaminergic and non-dopaminergic properties. It is primarily used in the treatment of Parkinson's disease as an add-on therapy to levodopa/carbidopa.

API suppliers (9)

Suppliers of Safinamide Mesylate evidenced by a US FDA Type II Drug Master File or an EU Certificate of Suitability (CEP). Sources: FDA DMF list, EDQM certification database.

Where these suppliers are
India6China1

Country recorded for 7 of 9 suppliers.

5 of 9 hold a GMP certificate on record in the EU or UK registers

Therapeutic areas

NeurologyMovement DisordersParkinson's Disease
Verified Supplier Partner

Do you supply Safinamide Mesylate? Get in front of buyers actively sourcing it.

We route real sourcing requests from pharma buyers to vetted, verified partners — qualified leads, not just a listing. Tell us what you make and we'll be in touch about becoming a Verified Supplier Partner.

No cost to enquire · we only reach out with a fit.

Ready to Accelerate Your
Discovery Workflow?

Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 7 days.